Sanofi, the French pharmaceutical company, has announced positive results from a late-stage clinical trial for its Sarclisa drug. The trial focused on the treatment of newly diagnosed multiple myeloma patients and demonstrated the drug’s ability to improve progression-free survival.
The trial, a phase 3 study, evaluated the use of Sarclisa in combination with standard-of-care drugs including bortezomib, lenalidomide, and dexamethasone. The results of a planned interim analysis showed that the combination therapy met its primary goal of improving progression-free survival compared to standard of care alone.
Sanofi also highlighted that the safety and tolerability of Sarclisa observed in the trial were consistent with its established safety profile. This further supports the drug’s potential as an effective treatment option.
Based on these promising results, Sanofi intends to use the study findings as the basis for a future regulatory submission. Dietmar Berger, Sanofi’s global head of development, expressed confidence in Sarclisa, stating, “This is the second phase 3 trial investigating Sarclisa in newly diagnosed patients to show superiority versus standard of care, reinforcing our belief in Sarclisa as a best-in-class medicine.”
These positive developments in the clinical trial mark an important step forward in the search for improved treatments for multiple myeloma patients. Further research and regulatory processes will be necessary to bring this potential new therapy to market.
